Savara Under Legal Investigation for Alleged Misleading Statements on Drug Approval Process

Savara Faces Legal Scrutiny Over Alleged Misleading Statements on Drug Approval Process

Savara Inc. is currently under investigation by national securities law firms Faruqi & Faruqi, LLP and Glancy Prongay & Murray LLP regarding alleged violations of federal securities laws. The focus of the investigation centers on the company’s Biologics License Application (BLA) for its drug MOLBREEVI, designed to treat autoimmune pulmonary alveolar proteinosis (PAP). Investors who acquired Savara securities between March 7, 2024, and May 23, 2025, and experienced losses are encouraged to seek legal counsel as the firms work to determine if there is a basis for class action lawsuits. The deadline for investors to join the lawsuit as lead plaintiffs is November 7, 2025.

The lawsuits claim that Savara executives made misleading statements concerning the BLA, particularly regarding its chemistry, manufacturing, and controls. The allegations suggest that insufficient details in the BLA led to the assumption that the FDA would likely reject the application in its current form. Furthermore, the complaint points to potential misrepresentation of the timeline for completing the BLA submission, which raises concerns over the company’s ability to secure additional capital in light of expected delays in regulatory approval. The culmination of these issues has led to skepticism about Savara's operational transparency and future prospects.

On May 27, 2025, following the announcement of an FDA refusal to file letter, Savara’s stock experienced a dramatic decline, plummeting by 31.69% to close at $1.94 per share. This significant drop underscores the potential impact of the alleged misleading statements on investor confidence and the overall market perception of Savara. As the investigations proceed, stakeholders are closely monitoring the situation to understand the implications for the company's future business operations and the broader context of regulatory compliance in the biotechnology sector.

In light of these developments, investors are reminded of their rights and options moving forward. Those interested in participating in the class action lawsuits are encouraged to contact legal representatives from Faruqi & Faruqi or Glancy Prongay & Murray for more information. The ongoing investigations serve as a cautionary tale about the importance of transparency in the biotechnology industry, especially as companies navigate complex regulatory frameworks to bring new treatments to market.